Imgatuzumab

Drug Profile

Imgatuzumab

Alternative Names: GA201; R7160; RG7160; RO-5083945

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GLYCART Biotechnology
  • Developer Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 01 Nov 2016 Roche withdraws a phase I trial in Non-small cell lung cancer (Late-stage disease, metastatic disease, combination therapy, first-line therapy) before enrollment in USA (NCT01702714) due to project team decision
  • 25 Jul 2013 Discontinued - Phase-I for Head and neck cancer in France, Italy, Netherlands, Spain and United Kingdom (IV)
  • 25 Jul 2013 Discontinued - Phase-II for Colorectal cancer (second-line therapy or greater, combination therapy, metastatic disease) in USA, Australia, Belgium, France, Germany, Italy, Poland, Spain and United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top